Cargando…

The COVID-19 risk in the cross-section of equity options

We use the implied volatility slope measures derived from US stock options to examine the impact of COVID-19 risk on the options market. The severity of COVID-19 is measured by the number of new confirmed cases. We find that equity options that are most sensitive to COVID-19 generate a more positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Jitsawatpaiboon, Kanokrak, Ruan, Xinfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908572/
https://www.ncbi.nlm.nih.gov/pubmed/36785797
http://dx.doi.org/10.1016/j.frl.2023.103684
_version_ 1784884391616446464
author Jitsawatpaiboon, Kanokrak
Ruan, Xinfeng
author_facet Jitsawatpaiboon, Kanokrak
Ruan, Xinfeng
author_sort Jitsawatpaiboon, Kanokrak
collection PubMed
description We use the implied volatility slope measures derived from US stock options to examine the impact of COVID-19 risk on the options market. The severity of COVID-19 is measured by the number of new confirmed cases. We find that equity options that are most sensitive to COVID-19 generate a more positive IV slope than less COVID-19-sensitive equity options. Moreover, this measure is more positive and significant during the lockdown period. Our findings suggest that the hedging cost of downside tail risk is more expensive during the high-uncertainty period, the time when COVID-19 is more intensive.
format Online
Article
Text
id pubmed-9908572
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99085722023-02-09 The COVID-19 risk in the cross-section of equity options Jitsawatpaiboon, Kanokrak Ruan, Xinfeng Financ Res Lett Article We use the implied volatility slope measures derived from US stock options to examine the impact of COVID-19 risk on the options market. The severity of COVID-19 is measured by the number of new confirmed cases. We find that equity options that are most sensitive to COVID-19 generate a more positive IV slope than less COVID-19-sensitive equity options. Moreover, this measure is more positive and significant during the lockdown period. Our findings suggest that the hedging cost of downside tail risk is more expensive during the high-uncertainty period, the time when COVID-19 is more intensive. The Author(s). Published by Elsevier Inc. 2023-05 2023-02-09 /pmc/articles/PMC9908572/ /pubmed/36785797 http://dx.doi.org/10.1016/j.frl.2023.103684 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Jitsawatpaiboon, Kanokrak
Ruan, Xinfeng
The COVID-19 risk in the cross-section of equity options
title The COVID-19 risk in the cross-section of equity options
title_full The COVID-19 risk in the cross-section of equity options
title_fullStr The COVID-19 risk in the cross-section of equity options
title_full_unstemmed The COVID-19 risk in the cross-section of equity options
title_short The COVID-19 risk in the cross-section of equity options
title_sort covid-19 risk in the cross-section of equity options
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908572/
https://www.ncbi.nlm.nih.gov/pubmed/36785797
http://dx.doi.org/10.1016/j.frl.2023.103684
work_keys_str_mv AT jitsawatpaiboonkanokrak thecovid19riskinthecrosssectionofequityoptions
AT ruanxinfeng thecovid19riskinthecrosssectionofequityoptions
AT jitsawatpaiboonkanokrak covid19riskinthecrosssectionofequityoptions
AT ruanxinfeng covid19riskinthecrosssectionofequityoptions